Boryung seeking sales of 100 billion won with new antihypertensive

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said on September 9 that its newly approved fimasartan, a new angiotensin II receptor blocker, is expected to generate 100 billion won ($87 million) in domestic sales within the next five years.

This already large market is predicted to continue growing rapidly as an increasingly aged and obese population is treated...